Becton, Dickinson and Company $BDX Shares Sold by Ameriprise Financial Inc.

Ameriprise Financial Inc. reduced its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 8.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,801,454 shares of the medical instruments supplier’s stock after selling 171,290 shares during the period. Ameriprise Financial Inc. owned about 0.63% of Becton, Dickinson and Company worth $412,627,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GQG Partners LLC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at $689,833,000. Kovitz Investment Group Partners LLC increased its holdings in Becton, Dickinson and Company by 392.4% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 3,416,665 shares of the medical instruments supplier’s stock worth $775,139,000 after purchasing an additional 2,722,829 shares during the period. Vanguard Group Inc. increased its holdings in Becton, Dickinson and Company by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock worth $6,414,322,000 after purchasing an additional 1,259,750 shares during the period. Nuveen LLC acquired a new stake in Becton, Dickinson and Company in the 1st quarter valued at about $211,097,000. Finally, GAMMA Investing LLC boosted its stake in shares of Becton, Dickinson and Company by 29,654.0% in the 1st quarter. GAMMA Investing LLC now owns 744,445 shares of the medical instruments supplier’s stock valued at $170,523,000 after buying an additional 741,943 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $196.4380 on Friday. The stock’s 50-day moving average is $180.10 and its two-hundred day moving average is $195.89. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The firm has a market cap of $56.31 billion, a price-to-earnings ratio of 35.33, a PEG ratio of 1.49 and a beta of 0.20.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.28. The business had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the business earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be issued a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio is presently 74.82%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 863 shares of the firm’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $192.30, for a total transaction of $165,954.90. Following the transaction, the director directly owned 23,143 shares of the company’s stock, valued at approximately $4,450,398.90. This trade represents a 3.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP David Shan sold 1,166 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the transaction, the executive vice president owned 4,575 shares in the company, valued at approximately $783,194.25. This represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,214 shares of company stock worth $579,206. Insiders own 0.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on BDX. Stifel Nicolaus cut their target price on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. William Blair downgraded shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 1st. Piper Sandler reaffirmed a “neutral” rating and set a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. The Goldman Sachs Group downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 target price for the company. in a research note on Friday, May 2nd. Finally, Morgan Stanley increased their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Four analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $211.44.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.